Oric Pharmaceuticals Stock Today
| ORIC Stock | USD 7.51 0.04 0.54% |
PerformanceVery Weak
| Odds Of DistressLow
|
Oric Pharmaceuticals is trading at 7.51 as of the 21st of March 2025, a 0.54 percent increase since the beginning of the trading day. The stock's open price was 7.47. Oric Pharmaceuticals has about a 21 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of April 2020 | Category Healthcare | Classification Health Care |
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. The company was incorporated in 2014 and is headquartered in South San Francisco, California. Oric Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 71.03 M outstanding shares of which 12.04 M shares are now shorted by private and institutional investors with about 8.51 trading days to cover. More on Oric Pharmaceuticals
Moving against Oric Stock
| 0.35 | CMRX | Chimerix Sell-off Trend | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Oric Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | MD MBA | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsOric Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Oric Pharmaceuticals' financial leverage. It provides some insight into what part of Oric Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Oric Pharmaceuticals (ORIC) is traded on NASDAQ Exchange in USA. It is located in 240 East Grand Avenue, South San Francisco, CA, United States, 94080 and employs 115 people. Oric Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 541.94 M. Oric Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 71.03 M outstanding shares of which 12.04 M shares are now shorted by private and institutional investors with about 8.51 trading days to cover.
Oric Pharmaceuticals currently holds about 227.06 M in cash with (112.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74.
Check Oric Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Oric Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Oric Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Oric Pharmaceuticals. Please pay attention to any change in the institutional holdings of Oric Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Oric Ownership Details
Oric Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-12-31 | 1.8 M | |
| Boxer Capital Management, Llc | 2024-12-31 | 1.7 M | |
| Boxer Capital Llc | 2024-09-30 | 1.7 M | |
| Superstring Capital Management Lp | 2024-12-31 | 1.6 M | |
| Nea Management Company, Llc | 2024-12-31 | 1.6 M | |
| Balyasny Asset Management Llc | 2024-12-31 | 1.6 M | |
| First Turn Management Llc | 2024-12-31 | 1.5 M | |
| Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 1.4 M | |
| T. Rowe Price Associates, Inc. | 2024-12-31 | 1.3 M | |
| Pfizer Inc | 2024-12-31 | 5.4 M | |
| Nextech Invest Ag | 2024-12-31 | 5.3 M |
Oric Pharmaceuticals Historical Income Statement
Oric Stock Against Markets
Oric Pharmaceuticals Corporate Management
| CPA CPA | Chief Officer | Profile | |
| BA BA | CoFounder Board | Profile | |
| Lori Friedman | Chief Officer | Profile | |
| Esq JD | G Counsel | Profile | |
| MS MD | Chief Officer | Profile | |
| Matthew Panuwat | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oric Pharmaceuticals. If investors know Oric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oric Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Oric Pharmaceuticals is measured differently than its book value, which is the value of Oric that is recorded on the company's balance sheet. Investors also form their own opinion of Oric Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oric Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oric Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oric Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oric Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oric Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.